RT info:eu-repo/semantics/article
T1 Motor Fluctuations Development Is Associated with Non-Motor Symptoms Burden Progression in Parkinson’s Disease Patients: A 2-Year Follow-Up Study
A1 Santos García, Diego
A1 Deus-Fonticoba, Teresa de
A1 Cores Bartolomé, Carlos
A1 Feal Painceiras, María
A1 Suárez Castro, Ester
A1 Canfield, Héctor
A1 Martínez Miró, Cristina
A1 Jesús, Silvia
A1 Aguilar, Miquel
A1 Pastor, Pau
A1 Planellás, Lluis L.
A1 Cosgaya, Marina
A1 García Caldentey, Juan
A1 Caballol, Núria
A1 Legarda, Inés
A1 Hernández Vara, Jorge
A1 Cabo López, Iria
A1 López Manzanares, Lydia
A1 González Aramburu, Isabel
A1 Ávila Rivera, María A.
A1 Gómez Mayordomo, Víctor
A1 Nogueira, Víctor
A1 Puente, Víctor
A1 Dotor, Julio
A1 Borrue, Carmen
A1 Solano Vila, Berta
A1 Álvarez Saúco, María
A1 Vela Desojo, Lydia
A1 Escalante Arroyo, Sonia
A1 Cubo Delgado, Esther
A1 Carrillo Padilla, Francisco
A1 Martínez Castrillo, Juan Carlos
A1 Sánchez Alonso, Pilar
A1 Alonso Losada, María Gema
A1 López Ariztegui, Nuria
A1 Gastón, Itziar
A1 Kulisevsky Bojarsky, Jaume
A1 Blázquez Estrada, Marta
A1 Seijo, Manuel
A1 Ruíz Martínez, Javier
A1 Valero, Caridad
A1 Kurtis, Mónica M.
A1 Fabregues, Oriol de
A1 González Ardura, Jessica
A1 Alonso Redondo, Rubén
A1 Ordás Bandera, Carlos Manuel
A1 López Díaz, Luis M.
A1 McAfee, Darrian
A1 Martínez Martín, Pablo
A1 Mir, Pablo
A1 COPPADIS Study Group
K1 Burden
K1 Follow-up
K1 Non-motor symptoms
K1 Motor fluctuations
K1 Parkinson’s disease
K1 Sistema nervioso-Enfermedades
K1 Nervous system-Diseases
K1 Medicina
K1 Medicine
K1 Neurología
K1 Neurology
AB Objective: The aim of the present study was to analyze the progression of non-motor symptoms (NMS) burden in Parkinson’s disease (PD) patients regarding the development of motor fluctuations (MF). Methods: PD patients without MF at baseline, who were recruited from January 2016 to November 2017 (V0) and evaluated again at a 2-year follow-up (V2) from 35 centers of Spain from the COPPADIS cohort, were included in this analysis. MF development at V2 was defined as a score ≥ 1 in the item-39 of the UPDRS-Part IV, whereas NMS burden was defined according to the Non-motor Symptoms Scale (NMSS) total score. Results: Three hundred and thirty PD patients (62.67 ± 8.7 years old; 58.8% males) were included. From V0 to V2, 27.6% of the patients developed MF. The mean NMSS total score at baseline was higher in those patients who developed MF after the 2-year follow-up (46.34 ± 36.48 vs. 34.3 ± 29.07; p = 0.001). A greater increase in the NMSS total score from V0 to V2 was observed in patients who developed MF (+16.07 ± 37.37) compared to those who did not develop MF (+6.2 ± 25.8) (p = 0.021). Development of MF after a 2-year follow-up was associated with an increase in the NMSS total score (β = 0.128; p = 0.046) after adjustment to age, gender, years from symptoms onset, levodopa equivalent daily dose (LEDD) and the NMSS total score at baseline, and the change in LEDD from V0 to V2. Conclusions: In PD patients, the development of MF is associated with a greater increase in the NMS burden after a 2-year follow-up.
PB MDPI
YR 2022
FD 2022-05
LK http://hdl.handle.net/10259/8822
UL http://hdl.handle.net/10259/8822
LA eng
NO The study was conducted according to the guidelines of the Declaration of Helsinki, and ap-proved by Comité de Ética de la Investigación Clínica de Galicia from Spain (2014/534; 2/DEC/2014).
DS Repositorio Institucional de la Universidad de Burgos
RD 09-may-2024